BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 17482465)

  • 1. Prospective multicenter trial to determine the feasibility of collection and predictive ability of breast fluid analysis in postmenopausal women receiving SERMs.
    Sauter ER; Ganz PA; Ehya H; Hewett JE; Schlatter L; Kliethermes B; Daly MB
    Breast; 2007 Oct; 16(5):489-94. PubMed ID: 17482465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers associated with breast cancer are associated with obesity.
    Sauter ER; Scott S; Hewett J; Kliethermes B; Ruhlen RL; Basarakodu K; de la Torre R
    Cancer Detect Prev; 2008; 32(2):149-55. PubMed ID: 18639389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-specific antigen production in the female breast: association with progesterone.
    Sauter ER; Babb J; Daly M; Engstrom PF; Ehya H; Malick J; Diamandis E
    Cancer Epidemiol Biomarkers Prev; 1998 Apr; 7(4):315-20. PubMed ID: 9568787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of reduced nipple aspirate fluid production and ductal lavage cellularity in women at high risk for breast cancer.
    Higgins SA; Matloff ET; Rimm DL; Dziura J; Haffty BG; King BL
    Breast Cancer Res; 2005; 7(6):R1017-22. PubMed ID: 16280052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological markers of risk in nipple aspirate fluid are associated with residual cancer and tumour size.
    Sauter ER; Ehya H; Babb J; Diamandis E; Daly M; Klein-Szanto A; Sigurdson E; Hoffman J; Malick J; Engstrom PF
    Br J Cancer; 1999 Dec; 81(7):1222-7. PubMed ID: 10584885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nipple aspirate fluid color is associated with breast cancer.
    Sauter ER; Winn JN; Dale PS; Wagner-Mann C
    Cancer Detect Prev; 2006; 30(4):322-8. PubMed ID: 16963197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Presence of epithelial cells in nipple aspirate fluid is associated with subsequent breast cancer: a 25-year prospective study.
    Buehring GC; Letscher A; McGirr KM; Khandhar S; Che LH; Nguyen CT; Hackett AJ
    Breast Cancer Res Treat; 2006 Jul; 98(1):63-70. PubMed ID: 16685591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of cytomorphology in specimens obtained by random periareolar fine needle aspiration and ductal lavage from women at high risk for development of breast cancer.
    Zalles CM; Kimler BF; Simonsen M; Clark JL; Metheny T; Fabian CJ
    Breast Cancer Res Treat; 2006 May; 97(2):191-7. PubMed ID: 16322885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen expression in nipple aspirate fluid is associated with advanced breast cancer.
    Sauter ER; Klein G; Wagner-Mann C; Diamandis EP
    Cancer Detect Prev; 2004; 28(1):27-31. PubMed ID: 15041074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of biomarkers for breast cancer in nipple aspiration and ductal lavage fluid.
    Li J; Zhao J; Yu X; Lange J; Kuerer H; Krishnamurthy S; Schilling E; Khan SA; Sukumar S; Chan DW
    Clin Cancer Res; 2005 Dec; 11(23):8312-20. PubMed ID: 16322290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen levels in nipple aspirate fluid correlate with breast cancer risk.
    Sauter ER; Daly M; Linahan K; Ehya H; Engstrom PF; Bonney G; Ross EA; Yu H; Diamandis E
    Cancer Epidemiol Biomarkers Prev; 1996 Dec; 5(12):967-70. PubMed ID: 8959318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leptin expression in breast nipple aspirate fluid (NAF) and serum is influenced by body mass index (BMI) but not by the presence of breast cancer.
    Sauter ER; Garofalo C; Hewett J; Hewett JE; Morelli C; Surmacz E
    Horm Metab Res; 2004 May; 36(5):336-40. PubMed ID: 15156414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nipple aspirate fluids from women with breast cancer contain increased levels of group IIa secretory phospholipase A2.
    Mannello F; Qin W; Zhu W; Fabbri L; Tonti GA; Sauter ER
    Breast Cancer Res Treat; 2008 Sep; 111(2):209-18. PubMed ID: 17932742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women.
    Bevers TB
    J Natl Compr Canc Netw; 2007 Sep; 5(8):719-24. PubMed ID: 17927929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activity.
    Stearns V; Gallagher A; Kleer CG; Singh B; Freedman M; Haddad BR; Isaacs C; Warren R; Brown M; Cullen J; Trock B; Hayes DF
    Clin Cancer Res; 2004 Dec; 10(24):8332-40. PubMed ID: 15623610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nipple aspirate fluid collection, related factors and relationship between carcinoembryonic antigen in nipple aspirate fluid and breast diseases in women in Harbin, PRC.
    Zhao YS; Pang D; Wang F; Xue YW; Gao DN; Li H; Li K; Wang BY; Wang D; Li HY
    Cancer Epidemiol Biomarkers Prev; 2009 Mar; 18(3):732-8. PubMed ID: 19273481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteomic analysis of nipple aspirate fluid from women with early-stage breast cancer using isotope-coded affinity tags and tandem mass spectrometry reveals differential expression of vitamin D binding protein.
    Pawlik TM; Hawke DH; Liu Y; Krishnamurthy S; Fritsche H; Hunt KK; Kuerer HM
    BMC Cancer; 2006 Mar; 6():68. PubMed ID: 16542425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The reliability of nipple aspirate and ductal lavage in women at increased risk for breast cancer--a potential tool for breast cancer risk assessment and biomarker evaluation.
    Visvanathan K; Santor D; Ali SZ; Brewster A; Arnold A; Armstrong DK; Davidson NE; Helzlsouer KJ
    Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):950-5. PubMed ID: 17507621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thomsen-Friedenreich and Tn antigens in nipple fluid: carbohydrate biomarkers for breast cancer detection.
    Kumar SR; Sauter ER; Quinn TP; Deutscher SL
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6868-71. PubMed ID: 16203776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
    Lee WL; Chao HT; Cheng MH; Wang PH
    Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.